ATE173255T1 - 3-(5-tetrazolyl-benzyl) aminopiperidin-derivate und tachykinin antagonisten - Google Patents

3-(5-tetrazolyl-benzyl) aminopiperidin-derivate und tachykinin antagonisten

Info

Publication number
ATE173255T1
ATE173255T1 AT94927627T AT94927627T ATE173255T1 AT E173255 T1 ATE173255 T1 AT E173255T1 AT 94927627 T AT94927627 T AT 94927627T AT 94927627 T AT94927627 T AT 94927627T AT E173255 T1 ATE173255 T1 AT E173255T1
Authority
AT
Austria
Prior art keywords
tetrazolyl
benzyl
tachykinin antagonists
aminopiperidine derivatives
aminopiperidine
Prior art date
Application number
AT94927627T
Other languages
English (en)
Inventor
Duncan Robert Armour
Brian Evans
Gerard Martin Paul Giblin
Michael Menteith Hann
Tania Hubbard
Xiao-Qing Lewell
David Middlemiss
Alan Naylor
Neil Anthony Pegg
Maria Victoria Vinader
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319606A external-priority patent/GB9319606D0/en
Priority claimed from GB9326583A external-priority patent/GB9326583D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE173255T1 publication Critical patent/ATE173255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT94927627T 1993-09-22 1994-09-20 3-(5-tetrazolyl-benzyl) aminopiperidin-derivate und tachykinin antagonisten ATE173255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939319606A GB9319606D0 (en) 1993-09-22 1993-09-22 Chemical compounds
GB9326583A GB9326583D0 (en) 1993-12-31 1993-12-31 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE173255T1 true ATE173255T1 (de) 1998-11-15

Family

ID=26303560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927627T ATE173255T1 (de) 1993-09-22 1994-09-20 3-(5-tetrazolyl-benzyl) aminopiperidin-derivate und tachykinin antagonisten

Country Status (30)

Country Link
US (2) US5703240A (de)
EP (1) EP0720609B1 (de)
JP (2) JP2865872B2 (de)
CN (1) CN1061041C (de)
AP (1) AP495A (de)
AT (1) ATE173255T1 (de)
AU (1) AU681190B2 (de)
BG (1) BG62169B1 (de)
CA (1) CA2172529A1 (de)
CO (1) CO4290298A1 (de)
CZ (1) CZ285479B6 (de)
DE (1) DE69414590T2 (de)
DK (1) DK0720609T3 (de)
ES (1) ES2123829T3 (de)
FI (1) FI961270A (de)
GR (1) GR3029354T3 (de)
HK (1) HK1004219A1 (de)
HR (1) HRP940575B1 (de)
HU (1) HU217428B (de)
IL (1) IL111002A (de)
IS (1) IS4208A (de)
NO (1) NO307830B1 (de)
NZ (1) NZ273614A (de)
OA (1) OA10576A (de)
PE (1) PE18295A1 (de)
PL (1) PL179585B1 (de)
SI (1) SI0720609T1 (de)
SK (1) SK280901B6 (de)
UA (1) UA44711C2 (de)
WO (1) WO1995008549A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
DE69633607T2 (de) * 1995-01-12 2006-02-23 Glaxo Group Ltd., Greenford Piperidinderivate mit tachykinin-antagonistischer wirkung
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
JP2000514047A (ja) * 1996-06-26 2000-10-24 ワーナー―ランバート・コンパニー 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998024441A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
CA2273806A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating substance use disorders
DK0942729T3 (da) * 1996-12-02 2005-01-10 Merck Sharp & Dohme Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser
EP0942730A1 (de) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bipolaren störungen
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AU732633B2 (en) * 1996-12-02 2001-04-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating schizophrenic disorders
CA2273351A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating sexual dysfunction
ATE285776T1 (de) * 1996-12-02 2005-01-15 Merck Sharp & Dohme Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
CA2287487A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
US6214846B1 (en) 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
AU2001292320A1 (en) * 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
AU2002247127A1 (en) * 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
WO2004041777A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
KR100785395B1 (ko) * 2003-08-01 2007-12-13 도요 가세이 고교 가부시키가이샤 알콕시-테트라졸-1-일-벤즈알데히드 화합물 및 그의제조방법
CN1580283A (zh) * 2003-08-13 2005-02-16 清华大学 一种检测核酸分子的方法
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2006137691A (ja) * 2004-11-11 2006-06-01 Toyo Kasei Kogyo Co Ltd ２−アルコキシ−５−テトラゾリル−ベンズアルデヒド化合物の製造方法
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP2155643B1 (de) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a-inhibitoren
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CA2728915A1 (en) * 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
MX2019015150A (es) 2017-06-30 2020-08-13 Chase Therapeutics Corp Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4117673A1 (de) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Behandlung von stammzellenmangel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
ATE142199T1 (de) * 1991-06-20 1996-09-15 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them

Also Published As

Publication number Publication date
HRP940575A2 (en) 1997-02-28
HRP940575B1 (en) 2000-06-30
NO961156D0 (no) 1996-03-21
ES2123829T3 (es) 1999-01-16
BG100487A (bg) 1996-12-31
IS4208A (is) 1995-03-23
OA10576A (en) 2002-06-03
NO961156L (no) 1996-05-21
NZ273614A (en) 1997-09-22
HU9600722D0 (en) 1996-05-28
CZ83096A3 (en) 1996-09-11
PL313619A1 (en) 1996-07-08
AP9400671A0 (en) 1994-10-31
DE69414590D1 (de) 1998-12-17
JP2865872B2 (ja) 1999-03-08
US5703240A (en) 1997-12-30
BG62169B1 (bg) 1999-04-30
JPH09505275A (ja) 1997-05-27
JPH11106341A (ja) 1999-04-20
CN1061041C (zh) 2001-01-24
PE18295A1 (es) 1995-07-27
CN1135218A (zh) 1996-11-06
PL179585B1 (pl) 2000-09-29
UA44711C2 (uk) 2002-03-15
DE69414590T2 (de) 1999-04-15
HK1004219A1 (en) 1998-11-20
CA2172529A1 (en) 1995-03-30
CO4290298A1 (es) 1996-04-17
GR3029354T3 (en) 1999-05-28
HUT75648A (en) 1997-05-28
IL111002A0 (en) 1994-11-28
AU681190B2 (en) 1997-08-21
US5843966A (en) 1998-12-01
CZ285479B6 (cs) 1999-08-11
EP0720609A1 (de) 1996-07-10
EP0720609B1 (de) 1998-11-11
IL111002A (en) 1998-09-24
NO307830B1 (no) 2000-06-05
SI0720609T1 (en) 1999-02-28
SK38396A3 (en) 1997-02-05
AU7697494A (en) 1995-04-10
WO1995008549A1 (en) 1995-03-30
AP495A (en) 1996-05-28
DK0720609T3 (da) 1999-07-26
FI961270A (fi) 1996-05-03
FI961270A0 (fi) 1996-03-19
SK280901B6 (sk) 2000-09-12
HU217428B (hu) 2000-01-28

Similar Documents

Publication Publication Date Title
ATE173255T1 (de) 3-(5-tetrazolyl-benzyl) aminopiperidin-derivate und tachykinin antagonisten
NO972526D0 (no) Tachykininantagonister
CY2004012I1 (el) Μορφολινικοι και θειομορφολινικοι ανταγωνιστες υποδοχεα ταχυκινινης
DE69332898D1 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
FI970310A (fi) 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina
DE69531331D1 (de) Phenylpiperidinderivate als neurokinin antagonists
ATE205185T1 (de) Benzamid-derivate und deren verwendung als vasopressin-antagonisten
DE68920529D1 (de) Blockcopolymere und Zusammensetzungen davon.
IL116917A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
ATE180973T1 (de) Paroxetin enthaltende tabletten und verfahren
BR9607347A (pt) Esteres e amidas de 1,4-piperidina dissubstítuída possuindo atividade antagonística 5-ht
EP0988295A4 (de) Durch einen heterozyklischen rest substituierte piperidine und ihre anwendung
DE68926733D1 (de) Piperidin-Derivate und diese enthaltende Hypotensiva
BR9708677A (pt) Piperidinas e pirrolidinas
BR9606815A (pt) Derivados de piperidina 4-(1H-indolil-1-il)-1-substituídos antipsicóticos
FI955679A (fi) Piperidiinijohdannaisia, niiden valmistus ja käyttö
DE69524590D1 (de) Zusammensetzung von 5htida und 5htid antagonisten
NO931364L (no) Tachykinin reseptorantagonister, isokinoloner og deres fremstilling
DE69029544D1 (de) Speicherarchitektur und Schaltung zum Hashcodieren
IS5077A (is) Öragna form tetrahýdrópýrídínafleiðu
KR970006301A (ko) -피페리딘 또는 테트라하이드로피리딘 아자비사이클로카복스아미드
DE69416131D1 (de) Piperidinyl-substituierte methanoanthracene als d1/d2-antagonisten und 5ht2-serotonin-antagonisten
IL115496A0 (en) Piperazine piperidine and tetrahydropyridine derivatives and their use
BR1100849A (pt) Derivado de piperidina, e, agente antiarrìtmico
SI0673928T1 (en) Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee